drugset / Trial / NCT05408026
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
Phase 1/2
Withdrawn
Alliance Foundation Trials, LLC.
Celgene Corporation · collabJanssen, LP · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II clinical trial design with a safety run-in period will be used to assess the rate of VGPR or better for the combination PVD-Dara in the treatment of RRMM.
Timeline
- Start
- 2022-10-01
- Primary completion
- 2025-10-01
- Completion
- 2026-02
Outcome
Outcome not reported
Stopped: “Study withdrawn, trial therapy deemed no longer novel and there was a lack of site interest.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Pomalidomide | Other / unclassified | — | — |